This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Medimmune Limited. Active years: 2019-2022.
Company Filing History:
Years Active: 2019-2022
Title: Joyson Karakunnel: Innovator in Cancer Treatment
Introduction
Joyson Karakunnel is a prominent inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment, particularly in the development of innovative therapies for non-small cell lung cancer. With a total of 2 patents to his name, Karakunnel is recognized for his groundbreaking work in immunotherapy.
Latest Patents
Karakunnel's latest patents focus on the use of anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer. These patents detail methods of treating this type of cancer by administering an effective amount of MEDI4736 or an antigen-binding fragment thereof, along with tremelimumab or an antigen-binding fragment thereof. His work aims to enhance the effectiveness of cancer treatments and improve patient outcomes.
Career Highlights
Joyson Karakunnel is associated with Medimmune Limited, where he has been instrumental in advancing cancer therapies. His research and innovations have positioned him as a key figure in the field of oncology, contributing to the development of novel treatment options for patients suffering from non-small cell lung cancer.
Collaborations
Karakunnel has collaborated with notable colleagues, including Rajesh Narwal and Paul Robbins. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pursuit of effective cancer treatments.
Conclusion
Joyson Karakunnel's contributions to cancer treatment through his patents and collaborations highlight his commitment to improving patient care. His work continues to inspire advancements in the field of oncology, making a significant impact on the lives of many.